WallStreetZenWallStreetZen

NASDAQ: PRTC
Puretech Health PLC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their PRTC stock forecasts and price targets.

Forecast return on equity

Is PRTC forecast to generate an efficient return?

Company
-474.15%
Industry
130.14%
Market
-52.51%
PRTC's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PRTC forecast to generate an efficient return on assets?

Company
-322.23%
Industry
47.48%
PRTC is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PRTC earnings per share forecast

What is PRTC's earnings per share in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$3.80-323.53%
Avg 2 year Forecast
-$2.30-235.29%

PRTC revenue forecast

What is PRTC's revenue in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
$3.7M-42.11%
Avg 2 year Forecast
$49.5M+674.53%
PRTC's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

PRTC revenue growth forecast

How is PRTC forecast to perform vs Biotechnology companies and vs the US market?

Company
104.68%
Industry
83.67%
Market
10.8%
PRTC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
PRTC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

PRTC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PRTC$14.79N/AN/A
DMAC$6.87$12.33+79.52%Strong Buy
BNTC$13.70$25.67+87.35%Buy
CGEM$5.93$27.17+358.13%Strong Buy
LRMR$4.08$17.00+316.67%Buy
View Top Biotech Stocks

Puretech Health Stock Forecast FAQ

What is PRTC's earnings growth forecast for 2025-2026?

(NASDAQ: PRTC) Puretech Health's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.2%.

Puretech Health's earnings in 2025 is $50,678,000.On average, 1 Wall Street analyst forecast PRTC's earnings for 2025 to be -$912,966,906, with the lowest PRTC earnings forecast at -$912,966,906, and the highest PRTC earnings forecast at -$912,966,906.

In 2026, PRTC is forecast to generate -$552,585,233 in earnings, with the lowest earnings forecast at -$552,585,233 and the highest earnings forecast at -$552,585,233.

If you're new to stock investing, here's how to buy Puretech Health stock.

What is PRTC's revenue growth forecast for 2025-2026?

(NASDAQ: PRTC) Puretech Health's forecast annual revenue growth rate of 104.68% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.8%.

Puretech Health's revenue in 2025 is $6,391,000.On average, 1 Wall Street analysts forecast PRTC's revenue for 2025 to be $888,941,461, with the lowest PRTC revenue forecast at $888,941,461, and the highest PRTC revenue forecast at $888,941,461.

In 2026, PRTC is forecast to generate $11,892,595,226 in revenue, with the lowest revenue forecast at $11,892,595,226 and the highest revenue forecast at $11,892,595,226.

What is PRTC's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: PRTC) forecast ROA is -322.23%, which is lower than the forecast US Biotechnology industry average of 47.48%.

What is PRTC's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: PRTC) Puretech Health's current Earnings Per Share (EPS) is $1.70. On average, analysts forecast that PRTC's EPS will be -$3.80 for 2025, with the lowest EPS forecast at -$3.80, and the highest EPS forecast at -$3.80. In 2026, PRTC's EPS is forecast to hit -$2.30 (min: -$2.30, max: -$2.30).

What is PRTC's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: PRTC) forecast ROE is -474.15%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.